Skip to main content
FAQs
Glossary
Close
FAQs
Why are some conditions more suitable for gene and cell therapies than others?
There is an approved treatment available for my condition - why can't I receive it?
How to look for approved medicines?
How are medicines developed and approved?
See all FAQs
Close
Glossary
Adeno-associated virus (AAV)
Adenovirus
Adult stem cells
Advanced Therapy Investigational Medicinal Product (ATIMP)
Advanced Therapy Medicinal Product (ATMP)
Antibody
Antigen
Base editors
Basic research
Cas9 nuclease
See full Glossary
EuroGCT
Menu
Close
Select language
English
Français
Deutsch
Italiano
Polski
Español
Português
Main navigation
Discover
Discover
Discover Gene and Cell Therapy
Educational Resources Directory
Educational Resources Directory
INTENS
INtestinal Tissue ENgineering Solution
LEARN
Listening to the experience of participants in neurosurgical trials
Discover Gene and Cell Therapy
Research Pathways
Research Pathways
Bringing new therapies from the lab to patients
EuroGCT Key Resources
EuroGCT Key Resources
ATMP Engage
Advanced Therapy Medicinal Products Patient and Public Involvement and Engagement Working Group
Actors and Network database
Actors and Networks database
Bringing new therapies from the lab to patients
About Us
Our team and partners
Contact
Condition
Alzheimer's Disease
Blood disorders
Bowel Disease
Cancer
Cerebral Palsy
Cord Blood
Cystic Fibrosis
Diabetes
Epidermolysis Bullosa
Eye Disease
Heart Disease
Huntington's Disease
Immune Conditions
Kidney Disease
Liver Disease
Lung Disease
Motor Neurone Disease
Multiple Sclerosis
Muscle and Skeletal Diseases
Muscular Dystrophy
Neurological Disorders
Parkinson's Disease
Rare Diseases
Sickle Cell Disease
Skin
Spinal Cord Injuries
Spinal Muscular Atrophy
Stroke
Reproduction and Fertility
Theme
Blood Stem Cells
CAR-T Therapy
Cell and Gene Fundamentals
Cell Therapy
Clinical Trials
Cord Blood
Current and Potential Uses
Disease Modelling
Embryonic Stem Cells
Ethics and Society
Explore Stem Cells
Factsheets
Gene Editing
Gene Therapy
Industry
iPS cells
Methods and Tools
MSCs
Organoids
Patient Involvement
Policy & Regulation
Reprogramming
Research
Skin Stem Cells
Spotlight on Research
Stem Cell News
Tissue Engineering
Unproven Treatments
Search
Select language
English
Français
Deutsch
Italiano
Polski
Español
Português
Breadcrumb
ATMP Engage
PPI Directory
Procedural advice on the evaluation of advanced therapy medicinal product in accordance with Article 8 of Regulation (EC) No 1394/2007
Procedural advice on the evaluation of advanced therapy medicinal product in accordance with Article 8 of Regulation (EC) No 1394/2007
The procedure on ATMP evaluation can be found on top of page 4
Go to resource
Back to top
Did you find the content on this page useful? If not, you can leave us a message so we can improve
Send us your thoughts